К содержанию
Dr. Tara EinullaevaMedical oncologist

Treatment 7 min

Cervical cancer: treatment of locally advanced and metastatic disease

Advanced cervical cancer: chemoradiotherapy, the role of pembrolizumab and induction chemotherapy, treatment of recurrence and metastases, preserving function and questions for your doctor.

Written and medically reviewed by

Dr. Tara Einullaeva

Medical oncologist, 9 years in practice. Credentials · reviewed 31 October 2026

Cervical cancer can look very different over the course of the disease: from a tiny tumour removed by surgery to widespread disease in the pelvis or metastases. This article is about situations where the tumour is already larger than early stage: locally advanced (within the pelvis) and metastatic.

The main difference from early stages is that the principal treatment here is not surgery but chemoradiotherapy. In recent years the approach has been changing: immunotherapy and sometimes chemotherapy before radiotherapy are added. Below is how it works, what to expect and what to ask.

How the stage is determined and why it decides everything

The stage is set by the FIGO classification (2018), which takes into account tumour size, spread to the parametria (tissue beside the uterus), vagina, pelvic walls, bladder, rectum and lymph nodes (TNM in plain words).

For an accurate assessment you usually need:

  • pelvic MRI: the best way to assess tumour size and spread around the cervix;
  • PET-CT or CT of the chest, abdomen and pelvis: to assess nodes and distant organs (what PET-CT shows);
  • pathology and, where possible, PD-L1 testing to decide on immunotherapy (PD-L1).

Staging errors happen because some clinicians judge tumour size by palpation alone. If the stage was set without pelvic MRI, it is worth clarifying.

Stages and the general treatment plan

Situation Main approach
Very early cancer, small size Surgery (in selected cases preserving the uterus)
IB3 up to IVA (locally advanced) Chemoradiotherapy (cisplatin and pelvic radiotherapy) plus brachytherapy
Pelvic lymph nodes involved Chemoradiotherapy, often with an extended radiation field
IVB, metastases Systemic treatment: chemotherapy ± bevacizumab ± immunotherapy
Recurrence after treatment Depends on site and volume: surgery, radiotherapy or systemic treatment

Chemoradiotherapy: the basis of treatment

The standard regimen in locally advanced cancer:

  • external pelvic radiotherapy over about five weeks, widened to the para-aortic nodes when needed;
  • weekly cisplatin given at the same time as radiotherapy (if cisplatin cannot be used, carboplatin or other options);
  • brachytherapy (internal radiotherapy), which delivers a high dose directly to the cervix. This is an important part of treatment: the quality and timing of brachytherapy affect the result, so the whole course is aimed to be completed within 8 weeks.

More on the drugs: platinum drugs and chemotherapy regimens.

What has changed in recent years

Immunotherapy together with chemoradiotherapy. In the KEYNOTE-A18 trial, in patients with locally advanced cervical cancer, adding pembrolizumab to chemoradiotherapy followed by a maintenance phase improved outcomes compared with chemoradiotherapy alone. This approach is included in current guidelines for the corresponding stages, but availability depends on the country and registration of the drug. More on how such treatment works: immunotherapy.

Induction chemotherapy. In the INTERLACE trial a short course of carboplatin with paclitaxel (weekly for six weeks) before standard chemoradiotherapy improved survival. This is an option for selected patients and is discussed at a tumour board.

The two approaches can overlap, so it is important to ask which option is recommended for you and why.

Metastatic and recurrent cervical cancer

If the disease is outside the pelvis or has returned and local treatment is not possible, systemic therapy is the basis.

First line:

  • platinum plus paclitaxel chemotherapy;
  • bevacizumab is added if there are no contraindications (risk of bleeding, fistulas, thrombosis), and it improves results (bevacizumab);
  • pembrolizumab is added to chemotherapy if the tumour is PD-L1 positive (in the KEYNOTE-826 trial this gave a survival advantage).

Second line and beyond:

  • tisotumab vedotin (an antibody-drug conjugate) where it is registered;
  • immunotherapy (for example cemiplimab) in selected situations;
  • other chemotherapy, clinical trials (about clinical trials).

If the disease returns in the pelvis after radiotherapy, pelvic exenteration (removal of several pelvic organs) is sometimes considered: a major operation for carefully selected patients, discussed at specialised centres.

At progression it is important to confirm it on scans and discuss the plan: progression on treatment.

Side effects and how to live with them

During chemoradiotherapy:

  • nausea and vomiting (anti-sickness drugs are chosen in advance);
  • diarrhoea and abdominal cramps;
  • frequent urge and burning when passing urine;
  • low white cells, anaemia;
  • fatigue and reduced appetite.

On diarrhoea in detail: diarrhoea during treatment. On fever: fever on chemotherapy.

Later:

  • vaginal dryness and narrowing after brachytherapy and radiotherapy. Prevention is regular use of dilators and moisturisers as your doctor advises; this is not an optional cosmetic extra but part of treatment;
  • lymphoedema (leg swelling) after radiotherapy and/or node surgery;
  • late bowel and bladder changes (rectal bleeding, frequent urination);
  • early menopause: hot flushes, dryness, lower bone density. The decision about hormone therapy is made individually.

On numb fingers: neuropathy in chemotherapy.

Fertility and sexual life

If the tumour is early and small, surgery that preserves the uterus (trachelectomy) is discussed. With pelvic radiotherapy the ovaries are often moved out of the radiation zone to preserve hormonal function. The ability to carry a pregnancy is usually lost after radiotherapy. Discuss options in advance: fertility preservation before chemotherapy.

Intimacy is also worth discussing with the doctor: after treatment there are effective ways to restore comfort, and there is no need to stay silent about it.

Follow-up after treatment

After chemoradiotherapy ends, the first assessment is usually made a few months later with MRI or PET-CT: the tumour can shrink slowly, and assessing too early gives an unclear picture. Check-ups are then more frequent in the first 2–3 years and less frequent later. Recurrence is more common in the early years but can occur later (recurrence after years).

What to ask your doctor

  • What is my FIGO stage and how was it confirmed (MRI, PET-CT)?
  • Why is chemoradiotherapy recommended rather than surgery (or the other way round)?
  • Is pembrolizumab or induction chemotherapy suitable for me?
  • How will brachytherapy be organised and when?
  • What can be done to preserve the ovaries?
  • Which side effects to expect and how to reduce late effects?
  • When and with what will the result be assessed?
  • Was PD-L1 tested?

When to seek urgent help

  • temperature of 38 °C or above, chills;
  • heavy vaginal bleeding;
  • inability to pass urine or severe abdominal pain;
  • severe diarrhoea or vomiting when you cannot drink;
  • shortness of breath, chest pain, swelling and pain in one leg (possible thrombosis, see thrombosis in cancer).

Can I get a second opinion

Yes, and with this disease it is often useful. Reasons: surgery is offered for an advanced tumour, the stage was set without MRI, immunotherapy and bevacizumab were not discussed, or the disease has returned. Prepare the pathology, MRI and PET-CT (discs and reports) and treatment summaries: documents for a second opinion, preparing for a consultation. If you need a review, book a consultation: I study the documents in advance and send a written summary. General information: gynaecological tumours.

Sources

  1. Cervical Cancer Treatment (PDQ) — National Cancer Institute
  2. ESMO Clinical Practice Guidelines — ESMO
  3. Practical guidelines for drug treatment of malignant tumours — RUSSCO (Russian Society of Clinical Oncology)
  4. Clinical guidelines (Russia) — Russian Ministry of Health

Frequently asked questions

This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.